Gene Biotechnology

Developer of IPS-derived immunotherapies to treat cancer

placeShenzhen, Guangdong Province, China calendar_todayFounded 2021 language genocury.com

Innovation

1 patent family (1 granted) — focus: Chemistry & metallurgy; filing pace dormant. Cited 13 times.

Investor mix

4 investors on record; lead investors include Efung Capital.

Investor typeCountShare
Venture capital375%
Private equity125%
Coming soon